US Patent Issued to Allogene Therapeutics on Oct. 21 for "Method of treatment using anti-CD19 rituximab-resistant chimeric antigen receptors" (California Inventors)

ALEXANDRIA, Va., Oct. 28 -- United States Patent no. 12,447,178, issued on Oct. 21, was assigned to Allogene Therapeutics Inc. (South San Francisco, Calif.).

"Method of treatment using anti-CD19 rituximab-resistant chimeric antigen receptors" was invented by Thomas Charles Pertel (San Mateo, Calif.), Barbra Johnson Sasu (San Francisco) and Mark W. Leonard (Burlingame, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are polynucleotides encoding chimeric antigen receptors (CARs) comprising a CD19 antigen binding domain that specifically binds to CD19 and is resistant to rituximab binding; and immune cells comprising these CD19-specific CARs, e.g., CAR-T cells. Also provided are methods of...